GS 1720
Alternative Names: GS-1720Latest Information Update: 07 Oct 2024
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III HIV infections
Most Recent Events
- 26 Sep 2024 Gilead Sciences plans a phase II/II trial for HIV-1 infections (Treatment naive) in October 2024 (PO) (NCT06613685)
- 20 Aug 2024 Phase-II/III clinical trials in HIV infections (Combination therapy) in Puerto Rico (PO) (NCT06544733)
- 20 Aug 2024 Phase-II/III clinical trials in HIV infections (Combination therapy) in USA (PO) (NCT06544733)